{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T05:41:26Z","timestamp":1790055686182,"version":"4.0.1"},"reference-count":84,"publisher":"American Society for Microbiology","issue":"7","license":[{"start":{"date-parts":[[2018,7,1]],"date-time":"2018-07-01T00:00:00Z","timestamp":1530403200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.asm.org\/non-commercial-tdm-license"}],"funder":[{"DOI":"10.13039\/100000011","name":"Howard Hughes Medical Institute","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000011","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006392","name":"AIDS Clinical Trials Group","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006392","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["journals.asm.org"],"crossmark-restriction":true},"short-container-title":["Antimicrob Agents Chemother"],"published-print":{"date-parts":[[2018,7]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n          <jats:p>The antileprosy drug clofazimine was recently repurposed as part of a newly endorsed short-course regimen for multidrug-resistant tuberculosis. It also enables significant treatment shortening when added to the first-line regimen for drug-susceptible tuberculosis in a mouse model. However, clofazimine causes dose- and duration-dependent skin discoloration in patients, and the optimal clofazimine dosing strategy in the context of the first-line regimen is unknown. We utilized a well-established mouse model to systematically address the impacts of duration, dose, and companion drugs on the treatment-shortening activity of clofazimine in the first-line regimen. In all studies, the primary outcome was relapse-free cure (culture-negative lungs) 6 months after stopping treatment, and the secondary outcome was bactericidal activity, i.e., the decline in the lung bacterial burden during treatment. Our findings indicate that clofazimine activity is most potent when coadministered with first-line drugs continuously throughout treatment and that equivalent treatment-shortening results are obtained with half the dose commonly used in mice. However, our studies also suggest that clofazimine at low exposures may have negative impacts on treatment outcomes, an effect that was evident only after the first 3 months of treatment. These data provide a sound evidence base to inform clofazimine dosing strategies to optimize the antituberculosis effect while minimizing skin discoloration. The results also underscore the importance of conducting long-term studies to allow the full evaluation of drugs administered in combination over long durations.<\/jats:p>","DOI":"10.1128\/aac.00636-18","type":"journal-article","created":{"date-parts":[[2018,5,4]],"date-time":"2018-05-04T08:35:29Z","timestamp":1525422929000},"update-policy":"https:\/\/doi.org\/10.1128\/asmj-crossmark-policy-page","source":"Crossref","is-referenced-by-count":44,"title":["Impact of Clofazimine Dosing on Treatment Shortening of the First-Line Regimen in a Mouse Model of Tuberculosis"],"prefix":"10.1128","volume":"62","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9359-9144","authenticated-orcid":false,"given":"Nicole C.","family":"Ammerman","sequence":"first","affiliation":[{"name":"Center for Tuberculosis Research, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA"},{"name":"KwaZulu-Natal Research Institute for TB-HIV, Durban, South Africa"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rosemary V.","family":"Swanson","sequence":"additional","affiliation":[{"name":"Center for Tuberculosis Research, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA"},{"name":"KwaZulu-Natal Research Institute for TB-HIV, Durban, South Africa"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elaine M.","family":"Bautista","sequence":"additional","affiliation":[{"name":"Center for Tuberculosis Research, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deepak V.","family":"Almeida","sequence":"additional","affiliation":[{"name":"Center for Tuberculosis Research, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA"},{"name":"KwaZulu-Natal Research Institute for TB-HIV, Durban, South Africa"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vikram","family":"Saini","sequence":"additional","affiliation":[{"name":"Center for Tuberculosis Research, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Till F.","family":"Omansen","sequence":"additional","affiliation":[{"name":"Center for Tuberculosis Research, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA"},{"name":"Department of Internal Medicine, Infectious Diseases Unit, University Medical Center, Groningen, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haidan","family":"Guo","sequence":"additional","affiliation":[{"name":"Center for Tuberculosis Research, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yong Seok","family":"Chang","sequence":"additional","affiliation":[{"name":"Center for Tuberculosis Research, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Si-Yang","family":"Li","sequence":"additional","affiliation":[{"name":"Center for Tuberculosis Research, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Asa","family":"Tapley","sequence":"additional","affiliation":[{"name":"Center for Tuberculosis Research, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA"},{"name":"Internal Medicine, Johns Hopkins Bayview Medical Center, Baltimore, Maryland, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rokeya","family":"Tasneen","sequence":"additional","affiliation":[{"name":"Center for Tuberculosis Research, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandeep","family":"Tyagi","sequence":"additional","affiliation":[{"name":"Center for Tuberculosis Research, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabrice","family":"Betoudji","sequence":"additional","affiliation":[{"name":"Center for Tuberculosis Research, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chivonne","family":"Moodley","sequence":"additional","affiliation":[{"name":"KwaZulu-Natal Research Institute for TB-HIV, Durban, South Africa"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bongani","family":"Ngcobo","sequence":"additional","affiliation":[{"name":"KwaZulu-Natal Research Institute for TB-HIV, Durban, South Africa"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Logan","family":"Pillay","sequence":"additional","affiliation":[{"name":"KwaZulu-Natal Research Institute for TB-HIV, Durban, South Africa"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Linda A.","family":"Bester","sequence":"additional","affiliation":[{"name":"Biomedical Resources Unit, School of Laboratory Medicine and Medical Sciences, College of Health Sciences, University of KwaZulu-Natal, Durban, South Africa"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sanil D.","family":"Singh","sequence":"additional","affiliation":[{"name":"Biomedical Resources Unit, School of Laboratory Medicine and Medical Sciences, College of Health Sciences, University of KwaZulu-Natal, Durban, South Africa"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard E.","family":"Chaisson","sequence":"additional","affiliation":[{"name":"Center for Tuberculosis Research, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1440-9889","authenticated-orcid":false,"given":"Eric","family":"Nuermberger","sequence":"additional","affiliation":[{"name":"Center for Tuberculosis Research, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacques H.","family":"Grosset","sequence":"additional","affiliation":[{"name":"Center for Tuberculosis Research, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA"},{"name":"KwaZulu-Natal Research Institute for TB-HIV, Durban, South Africa"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"235","reference":[{"key":"e_1_3_3_2_2","volume-title":"Guidelines for treatment of drug-susceptible tuberculosis and patient care, 2017 update","author":"World Health Organization","year":"2017","unstructured":"World Health Organization. 2017. Guidelines for treatment of drug-susceptible tuberculosis and patient care, 2017 update. World Health Organization Press, Geneva, Switzerland."},{"key":"e_1_3_3_3_2","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.01356-2016"},{"key":"e_1_3_3_4_2","doi-asserted-by":"publisher","DOI":"10.5588\/ijtld.12.0776"},{"key":"e_1_3_3_5_2","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0014014"},{"key":"e_1_3_3_6_2","volume-title":"Global tuberculosis report 2017","author":"World Health Organization","year":"2017","unstructured":"World Health Organization. 2017. Global tuberculosis report 2017. World Health Organization Press, Geneva, Switzerland."},{"key":"e_1_3_3_7_2","volume-title":"October 2016 revision","author":"World Health Organization","year":"2016","unstructured":"World Health Organization. 2016. WHO treatment guidelines for drug-resistant tuberculosis, 2016 update. October 2016 revision. World Health Organization Press, Geneva, Switzerland."},{"key":"e_1_3_3_8_2","doi-asserted-by":"publisher","DOI":"10.5588\/ijtld.17.0498"},{"key":"e_1_3_3_9_2","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciu843"},{"key":"e_1_3_3_10_2","doi-asserted-by":"publisher","DOI":"10.5588\/ijtld.14.0535"},{"key":"e_1_3_3_11_2","doi-asserted-by":"publisher","DOI":"10.5588\/ijtld.13.0075"},{"key":"e_1_3_3_12_2","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.201001-0077OC"},{"key":"e_1_3_3_13_2","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.201304-0753OC"},{"key":"e_1_3_3_14_2","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1416951112"},{"key":"e_1_3_3_15_2","first-page":"287","article-title":"Long-term clinical toxicity studies with clofazimine (B663) in leprosy","volume":"44","author":"Hastings RC","year":"1976","unstructured":"Hastings RC, Jacobson RR, Trautman JR. 1976. Long-term clinical toxicity studies with clofazimine (B663) in leprosy. Int J Lepr Other Mycobact Dis 44:287\u2013293.","journal-title":"Int J Lepr Other Mycobact Dis"},{"key":"e_1_3_3_16_2","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2013-004143"},{"key":"e_1_3_3_17_2","doi-asserted-by":"publisher","DOI":"10.1016\/0190-9622(90)70204-U"},{"key":"e_1_3_3_18_2","volume-title":"International package leaflet","author":"Novartis Drug Regulatory Affairs","year":"2005","unstructured":"Novartis Drug Regulatory Affairs. 2005. Lamprene (clofazimine) 50 or 100 mg capsules, soft. International package leaflet. Novartis, Basel, Switzerland."},{"key":"e_1_3_3_19_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00260-15"},{"key":"e_1_3_3_20_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01692-17"},{"key":"e_1_3_3_21_2","first-page":"567","article-title":"Activit\u00e9 antituberculeuse exp\u00e9rimentale de deux d\u00e9riv\u00e9s de ph\u00e9nazine pigment\u00e9e (B 663 et B 720) seuls et associ\u00e9s a d'autres antituberculeux (isoniazide et \u00e9thioniamide)","volume":"99","author":"Grumbach F","year":"1960","unstructured":"Grumbach F. 1960. Activit\u00e9 antituberculeuse exp\u00e9rimentale de deux d\u00e9riv\u00e9s de ph\u00e9nazine pigment\u00e9e (B 663 et B 720) seuls et associ\u00e9s a d'autres antituberculeux (isoniazide et \u00e9thioniamide). Ann Inst Pasteur (Paris) 99:567\u2013585.","journal-title":"Ann Inst Pasteur (Paris)"},{"key":"e_1_3_3_22_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkw417"},{"key":"e_1_3_3_23_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00753-16"},{"key":"e_1_3_3_24_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00699-11"},{"key":"e_1_3_3_25_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijid.2016.08.027"},{"key":"e_1_3_3_26_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.02565-14"},{"key":"e_1_3_3_27_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00177-16"},{"key":"e_1_3_3_28_2","doi-asserted-by":"publisher","DOI":"10.1007\/978-1-4615-7511-5_2"},{"key":"e_1_3_3_29_2","first-page":"5","article-title":"The sterilizing value of rifampicin and pyrazinamide in experimental short-course chemotherapy","volume":"53","author":"Grosset J","year":"1978","unstructured":"Grosset J. 1978. The sterilizing value of rifampicin and pyrazinamide in experimental short-course chemotherapy. Bull Int Union Tuberc 53:5\u201312.","journal-title":"Bull Int Union Tuberc"},{"key":"e_1_3_3_30_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00830-09"},{"key":"e_1_3_3_31_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.02637-15"},{"key":"e_1_3_3_32_2","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.200807-1152OC"},{"key":"e_1_3_3_33_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00898-06"},{"key":"e_1_3_3_34_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(12)61080-0"},{"key":"e_1_3_3_35_2","doi-asserted-by":"publisher","DOI":"10.1021\/acsinfecdis.5b00127"},{"key":"e_1_3_3_36_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00384-12"},{"key":"e_1_3_3_37_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.03822-14"},{"key":"e_1_3_3_38_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.05293-11"},{"key":"e_1_3_3_39_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2015.12.056"},{"key":"e_1_3_3_40_2","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms12393"},{"key":"e_1_3_3_41_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkw244"},{"key":"e_1_3_3_42_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00507-11"},{"key":"e_1_3_3_43_2","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1521988112"},{"key":"e_1_3_3_44_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkl358"},{"key":"e_1_3_3_45_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00395-15"},{"key":"e_1_3_3_46_2","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M110.200501"},{"key":"e_1_3_3_47_2","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M406796200"},{"key":"e_1_3_3_48_2","doi-asserted-by":"publisher","DOI":"10.1038\/emi.2017.24"},{"key":"e_1_3_3_49_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkv054"},{"key":"e_1_3_3_50_2","doi-asserted-by":"publisher","DOI":"10.1128\/microbiolspec.TBTB2-0014-2016"},{"key":"e_1_3_3_51_2","doi-asserted-by":"publisher","DOI":"10.1164\/ajrccm\/143.4_Pt_1.700"},{"key":"e_1_3_3_52_2","doi-asserted-by":"publisher","DOI":"10.1016\/0041-3879(86)90027-9"},{"key":"e_1_3_3_53_2","first-page":"165","article-title":"Controlled clinical trial of five short-course (4-month) chemotherapy regimens in pulmonary tuberculosis. Second report of the 4th study","volume":"123","author":"East African\/British Medical Research Councils Study","year":"1981","unstructured":"East African\/British Medical Research Councils Study. 1981. Controlled clinical trial of five short-course (4-month) chemotherapy regimens in pulmonary tuberculosis. Second report of the 4th study. Am Rev Respir Dis 123:165\u2013170.","journal-title":"Am Rev Respir Dis"},{"key":"e_1_3_3_54_2","doi-asserted-by":"publisher","DOI":"10.1016\/0041-3879(81)90016-7"},{"key":"e_1_3_3_55_2","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1159\/000324894","volume-title":"Antituberculosis chemotherapy","author":"Ahmad Z","year":"2011","unstructured":"Ahmad Z, Makaya NH, Grosset J. 2011. History of drug discovery: early evaluation studies and lessons learnt from them, p 2\u20139. In Donald PR, Van Helden PD (ed), Antituberculosis chemotherapy, vol 40. Karger, Basel, Switzerland."},{"key":"e_1_3_3_56_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00913-17"},{"key":"e_1_3_3_57_2","doi-asserted-by":"publisher","DOI":"10.2165\/00003088-200342090-00003"},{"key":"e_1_3_3_58_2","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.200602-280OC"},{"key":"e_1_3_3_59_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.06383-11"},{"key":"e_1_3_3_60_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejps.2013.01.017"},{"key":"e_1_3_3_61_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.05792-11"},{"key":"e_1_3_3_62_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01830-15"},{"key":"e_1_3_3_63_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.02278-13"},{"key":"e_1_3_3_64_2","doi-asserted-by":"publisher","DOI":"10.1124\/dmd.117.077834"},{"key":"e_1_3_3_65_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.tube.2015.08.004"},{"key":"e_1_3_3_66_2","first-page":"67","article-title":"Effect of clofazimine and dapsone on rifampicin (Lositril) pharmacokinetics in multibacillary and paucibacillary leprosy cases","volume":"57","author":"Mehta J","year":"1986","unstructured":"Mehta J, Gandhi IS, Sane SB, Wamburkar MN. 1986. Effect of clofazimine and dapsone on rifampicin (Lositril) pharmacokinetics in multibacillary and paucibacillary leprosy cases. Lepr Rev 57:67\u201376.","journal-title":"Lepr Rev"},{"key":"e_1_3_3_67_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/18.6.715"},{"key":"e_1_3_3_68_2","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.201204-0682OC"},{"key":"e_1_3_3_69_2","volume-title":"Multidrug therapy against leprosy: development and implementation over the past 25 years","author":"World Health Organization","year":"2004","unstructured":"World Health Organization. 2004. Multidrug therapy against leprosy: development and implementation over the past 25 years. World Health Organization Press, Geneva, Switzerland."},{"key":"e_1_3_3_70_2","doi-asserted-by":"publisher","DOI":"10.2165\/00003088-198916020-00002"},{"key":"e_1_3_3_71_2","doi-asserted-by":"publisher","DOI":"10.1007\/978-1-4615-7511-5_3"},{"key":"e_1_3_3_72_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00038-17"},{"key":"e_1_3_3_73_2","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/cir184"},{"key":"e_1_3_3_74_2","doi-asserted-by":"publisher","DOI":"10.3109\/03602539508994208"},{"key":"e_1_3_3_75_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0378-4347(00)86030-2"},{"key":"e_1_3_3_76_2","first-page":"9","article-title":"Pharmacokinetics of clofazimine in healthy volunteers","volume":"55","author":"Schaad-Lanyi Z","year":"1987","unstructured":"Schaad-Lanyi Z, Dieterle W, Dubois JP, Theobald W, Vischer W. 1987. Pharmacokinetics of clofazimine in healthy volunteers. Int J Lepr Other Mycobact Dis 55:9\u201315.","journal-title":"Int J Lepr Other Mycobact Dis"},{"key":"e_1_3_3_77_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.tube.2004.04.001"},{"key":"e_1_3_3_78_2","doi-asserted-by":"publisher","DOI":"10.4269\/ajtmh.1974.23.1110"},{"key":"e_1_3_3_79_2","doi-asserted-by":"publisher","DOI":"10.1126\/science.1106753"},{"key":"e_1_3_3_80_2","doi-asserted-by":"publisher","DOI":"10.1038\/nm.3937"},{"key":"e_1_3_3_81_2","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.201410-1801OC"},{"key":"e_1_3_3_82_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01370-15"},{"key":"e_1_3_3_83_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.40.3.552"},{"key":"e_1_3_3_84_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.36.3.548"},{"key":"e_1_3_3_85_2","doi-asserted-by":"publisher","DOI":"10.1099\/00222615-5-2-165"}],"container-title":["Antimicrobial Agents and Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/AAC.00636-18","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/AAC.00636-18","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,2,21]],"date-time":"2022-02-21T21:19:11Z","timestamp":1645478351000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.asm.org\/doi\/10.1128\/AAC.00636-18"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,7]]},"references-count":84,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2018,7]]}},"alternative-id":["10.1128\/AAC.00636-18"],"URL":"https:\/\/doi.org\/10.1128\/aac.00636-18","relation":{},"ISSN":["0066-4804","1098-6596"],"issn-type":[{"value":"0066-4804","type":"print"},{"value":"1098-6596","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,7]]},"assertion":[{"value":"2018-03-31","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2018-04-30","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2018-06-26","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e00636-18"}}